Atrium Therapeutics, Inc. filed a Form 8-K on October 27, 2026, announcing that the first patient has been dosed in the company's Phase 1/2 Corventis clinical trial evaluating ATR-1072 for the potential treatment of PRKAG2 syndrome.

Key Highlights

  • First patient dosed: Atrium Therapeutics announced that the first patient has been dosed in the Phase 1/2 Corventis clinical trial.
  • Investigational therapy: The trial evaluates ATR-1072, described as the company's lead investigational therapy.
  • Target indication: The therapy is being evaluated for the potential treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome.
  • Event date: The announcement was made on October 27, 2026, the date of the earliest event reported.
  • Signatory: The filing was signed by Kathleen Gallagher, Chief Executive Officer of Atrium Therapeutics, Inc.
  • Exchange listing: The company's common stock, par value $0.001 per share, trades on NASDAQ:RNA on the Nasdaq Global Select Market.

Atrium Therapeutics Initiates Corventis Phase 1/2 Trial for PRKAG2 Syndrome

According to the filing, Atrium Therapeutics, Inc. issued a press release on October 27, 2026, reporting the dosing of the first patient in its Phase 1/2 Corventis clinical trial. The trial is evaluating ATR-1072, which the company disclosed is its lead investigational therapy. The indication under study is PRKAG2 syndrome, identified in the filing by its full name: Protein Kinase AMP-activated non-catalytic subunit Gamma 2 syndrome.

The 8-K was filed under Item 8.01 (Other Events) and attaches the press release as Exhibit 99.1, which the filing states is incorporated by reference. The registrant is an emerging growth company incorporated in Delaware, headquartered at 10578 Science Center Drive, Suite 125, San Diego, California 92121, according to the filing. The company has elected not to use the extended transition period for complying with new or revised financial accounting standards, as indicated by the unchecked box on the cover page.

Chief Executive Officer Kathleen Gallagher signed the report on behalf of Atrium Therapeutics. No financial statements were included with this filing; the only exhibits listed are the press release (Exhibit 99.1) and the Cover Page Interactive Data File (Exhibit 104).

What Was Disclosed

Atrium Therapeutics filed an 8-K on October 27, 2026, disclosing the first patient dosing in the Phase 1/2 Corventis clinical trial of ATR-1072 for the potential treatment of PRKAG2 syndrome. A press release dated the same day was attached as Exhibit 99.1.